Stuart Spechler, MD, professor of internal medicine at the University of Texas Southwestern in Dallas and chief of gastroenterology at Dallas VA Medical Center, was senior author of the study. Dr. Spechler and colleagues examined patients at the Dallas VA Medical Center who had reflux esophagitis that PPIs successfully treated. The researchers stopped treating patients with PPIs to analyze the effect.
Here are three points:
1. In 11 of 12 patients with reflux esophagitis, changes to the esophagus reoccurred after the researchers stopped the PPIs.
2. The changes that reoccurred were not consistent with the chemical burns associated with the stomach acid backing up through the esophagus.
3. The researchers’ findings support the new idea that refluxed stomach acid stimulates the esophagus to make cytokines, which then sets up the inflammation process.
More articles on GI & endoscopy:
Exact Sciences’ total revenues reach $14.8M in Q1 2016, FDA clears EndoGastric Solutions’ EsophyX Z device & more — 8 GI company key notes
Southern California Gastroenterology Associates changes name: 4 notes
Nelson Lab, Healthmark introduce kit for duodenoscope testing: 3 points
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.